ARS Pharmaceuticals, Inc (SPRY NASDAQ) stock market data APIs
$9.1465
0.47(5.1%)
as of October 24, 2025
Try our APIs with
free plan!
ARS Pharmaceuticals, Inc Financial Data Overview
Price chart is built with
Anychart
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Prev. Close
9.1465
Open
9.6149
High
9.6769
Low
9.0162
52 wk Range
9.08-18.9
Market Cap
900 M
Shares Outstanding
98 826 K
Revenue
112 M
EPS
-0.46
Beta
0.841
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ARS Pharmaceuticals, Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ARS Pharmaceuticals, Inc data using free add-ons & libraries
Get ARS Pharmaceuticals, Inc Fundamental Data
ARS Pharmaceuticals, Inc Fundamental data includes:
- Net Revenue: 112 M
- EBITDA: -58 733 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.46
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARS Pharmaceuticals, Inc News
New
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
ARS Pharmaceuticals, Inc. SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients ...
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed?
On September 29, 2025, ARS Pharmaceuticals announced it secured a senior secured term loan facility of up to US$250 million with affiliates of RA Capital Management and OMERS Life Sciences, receiving ...
2 Penny Stocks That Wall Street Believes Can Soar Over 200%
Penny stocks, which are deemed highly volatile, are shares of small companies that trade at a low price. They usually trade under $5 per share in the U.S. Penny biotech stocks, in particular, are typ...
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies
– RA Capital and OMERS Life Sciences provide up to $250 million loan facility to commercial-stage biopharma company ARS Pharma to propel further growth – BOSTON, Sept. 30, 2025 /PRNewswire/ -- RA...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
